Orforglipron
Orforglipron (oral non-peptide GLP-1 agonist)
An investigational once-daily oral GLP-1 receptor agonist that is a small molecule rather than a peptide, studied for obesity and diabetes.
Overview
Orforglipron is an oral GLP-1 receptor agonist (FDA-approved April 2026 as Foundayo) notable for being a small-molecule pill rather than an injected peptide, which could make GLP-1 therapy easier to scale. Phase 2 and Phase 3 trials have reported meaningful weight loss and glucose lowering. It is included here because it competes directly with the peptide GLP-1 drugs. Update, September 2026: the FDA approved orforglipron on April 1, 2026 under the brand name Foundayo, about 10 weeks after the NDA was received on January 20, 2026, under the National Priority Voucher program, making it the first oral small-molecule GLP-1 agonist. ATTAIN-1 reported 12.4% weight loss at 72 weeks on the 36 mg dose by the efficacy estimand (11.2% versus 2.1% for placebo in the NEJM treatment-regimen analysis).
Mechanism of action
Activates the GLP-1 receptor as an orally available small molecule, reducing appetite and improving glucose-dependent insulin secretion.
Key studies & citations
- Human2023
Daily oral GLP-1 receptor agonist orforglipron for adults with obesity
Phase 2: 9.4% to 14.7% weight loss at 36 weeks across doses versus 2.3% with placebo; GI events mostly mild to moderate.
New England Journal of Medicine - Human2025
Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1)
Phase 3, 3,127 adults: 11.2% weight loss at 72 weeks on 36 mg versus 2.1% with placebo (treatment-regimen estimand); 36% lost 15% or more.
New England Journal of Medicine - Human2025
Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes (ACHIEVE-1)
Phase 3: HbA1c fell 1.24 to 1.48 points at 40 weeks versus 0.41 with placebo.
New England Journal of Medicine - Human2026
FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
April 1, 2026 approval announcement; quotes 12.4% (27.3 lb) weight loss on the highest dose in ATTAIN-1 by the efficacy estimand.
Eli Lilly press release - Human2026
NDA 220934 approval letter: Foundayo (orforglipron) tablets
FDA approval letter for chronic weight management in adults with obesity or overweight with a weight-related comorbidity; NDA received January 20, 2026.
FDA (Drugs@FDA)
Frequently asked questions
Is orforglipron a peptide?
No. It is a small-molecule pill, unlike peptide GLP-1 drugs such as semaglutide. Its appeal is oral dosing without the manufacturing limits of peptides.